Shahriyar Bourbour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shahriyar Bourbour has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Shirin Farivar
Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
2 shared publications - Afshan Shirkavand
Department of Photodynamic, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran
1 shared publication - Amir Mohammad Akbari
Department of Cellular and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran P.O. Box 1658953571, Iran
1 shared publication Auob Rustamzadeh
1 shared publication- Ezeddin Mohajerani
Laser and Plasma Research Institute, Shahid Beheshti University, Tehran, Iran
1 shared publication - Farhad Seif
Department of Photodynamic, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. ume 20, 1-16
Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis
Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis, even with many therapeutic interventions, including surgery, chemotherapy, and radiotherapy. Recent immunotherapies have broaden horizons to the utilization of the immune system to eradicate GBM. However, the clinical efficacy of such approaches is limited, owing to the tumor’s multifaceted immunosuppressive microenvironment and the blood-brain barrier (BBB) structure. The dysfunction of immune cells, especially T cells and natural killer (NK) cells, is significantly influenced by the immunosuppressive mechanisms in GBM. Novel therapeutic strategies are needed to overcome these mechanisms. In the current review, we explore the main functions of T cells, especially cytotoxic CD4+ and helper CD8+ T cells, alongside NK cells, in response to GBM. We further discuss the mechanisms contributing to their dysfunction, focusing on T cell exhaustion, altered receptor expression, and metabolic reprogramming within the GBM microenvironment to establish diagnostic and prognostic biomarkers. Moreover, we highlight recent advances in immunotherapeutic approaches, including immune checkpoint inhibitors (ICI), miRNA therapy, oncolytic viruses, and Chimeric Antigen Receptor (CAR) T/NK cell therapy to provide new opportunities for enhancing GBM treatment and biomarker-guided precision medicine.
- 1 May 2026
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. ume 20, 1-16
Open AccessImmunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis
Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis, even with many therapeutic interventions, including surgery, chemotherapy, and radiotherapy. Recent immunotherapies have broaden horizons to the utilization of the immune system to eradicate GBM. However, the clinical efficacy of such approaches is limited, owing to the tumor’s multifaceted immunosuppressive microenvironment and the blood-brain barrier (BBB) structure. The dysfunction of immune cells, especially T cells and natural killer (NK) cells, is significantly influenced by the immunosuppressive mechanisms in GBM. Novel therapeutic strategies are needed to overcome these mechanisms. In the current review, we explore the main functions of T cells, especially cytotoxic CD4+ and helper CD8+ T cells, alongside NK cells, in response to GBM. We further discuss the mechanisms contributing to their dysfunction, focusing on T cell exhaustion, altered receptor expression, and metabolic reprogramming within the GBM microenvironment to establish diagnostic and prognostic biomarkers. Moreover, we highlight recent advances in immunotherapeutic approaches, including immune checkpoint inhibitors (ICI), miRNA therapy, oncolytic viruses, and Chimeric Antigen Receptor (CAR) T/NK cell therapy to provide new opportunities for enhancing GBM treatment and biomarker-guided precision medicine.
- Open Access
- 8 December 2025
- Published by Springer Nature in BMC Biotechnology
- Vol. 26 (1)
Effects of optogenetic stimulation on neural gene expression in human bone marrow and adipose-derived mesenchymal stem cells
Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) and adipose tissue are widely applied in tissue engineering. Optogenetics enables millisecond-scale sp
- 8 December 2025
- Published by Springer Nature in BMC Biotechnology
- Vol. 26 (1)
Open AccessEffects of optogenetic stimulation on neural gene expression in human bone marrow and adipose-derived mesenchymal stem cells
Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) and adipose tissue are widely applied in tissue engineering. Optogenetics enables millisecond-scale sp